title: Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.
abstract: A four-yr-old boy developed a solitary metastasis nine months after living-related liver transplantation for unresectable hepatoblastoma. After resection of the metastatic lesion, he received an auto-PBSCT with a double-conditioning regimen consisting of melphalan and thiotepa. Auto-PBSCT could be safely performed without any serious regimen-related toxicity or infection. However, transient cessation of tacrolimus during myelosuppression resulted in graft rejection of the liver just after hematological engraftment, but rejection was resolved by tacrolimus and methylprednisolone. The patient is alive and free from disease two yr after auto-PBSCT without any signs of graft rejection. High-dose chemotherapy using this conditioning regimen may be feasible for recurrent hepatoblastoma after liver transplantation in terms of safety and anti-tumor activity.
authors.affiliation: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Niwa
authors.forename: Katsutsugu
authors.initials: K
authors.lastname: Umeda
authors.forename: Tomonari
authors.initials: T
authors.lastname: Awaya
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yui
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsubara
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Hiramatsu
authors.forename: Ken-Ichiro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Souichi
authors.initials: S
authors.lastname: Adachi
authors.forename: Takashi
authors.initials: T
authors.lastname: Itoh
authors.forename: Shinji
authors.initials: S
authors.lastname: Uemoto
authors.forename: Tatsutoshi
authors.initials: T
authors.lastname: Nakahata
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002675:Child, Preschool; D006084:Graft Rejection; D018197:Hepatoblastoma / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011379:Prognosis; D012008:Recurrence; D016559:Tacrolimus / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016559:Tacrolimus